Neurogene (NASDAQ:NGNE – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Neurogene to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, institutional ownership and profitability.
Profitability
This table compares Neurogene and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurogene | N/A | -45.10% | -41.00% |
| Neurogene Competitors | -9,046.59% | -199.78% | -30.61% |
Institutional & Insider Ownership
52.4% of Neurogene shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Neurogene and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurogene | 1 | 0 | 5 | 2 | 3.00 |
| Neurogene Competitors | 9782 | 15052 | 45296 | 1571 | 2.54 |
Neurogene presently has a consensus price target of $80.29, suggesting a potential upside of 201.03%. As a group, “Biotechnology” companies have a potential upside of 97.59%. Given Neurogene’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than its peers.
Volatility & Risk
Neurogene has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Neurogene’s peers have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
Earnings & Valuation
This table compares Neurogene and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Neurogene | $930,000.00 | -$90.35 million | -5.30 |
| Neurogene Competitors | $691.14 million | $10.43 million | -10.02 |
Neurogene’s peers have higher revenue and earnings than Neurogene. Neurogene is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Neurogene beats its peers on 7 of the 12 factors compared.
Neurogene Company Profile
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
